Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NORTH CHICAGO, ILL., MAY 6, 2026 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) WILL PARTICIPATE IN THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 13, 2026.

ABBVIE TO PRESENT AT THE BANK OF AMERICA SECURITIES HEALTHCARE CONFERENCE

ABBVIE PRESENTS 18 ABSTRACTS IN CROHN'S DISEASE AND ULCERATIVE COLITIS BREADTH OF DATA FROM REAL-WORLD EVIDENCE AND CLINICAL TRIALS REINFORCE RISANKIZUMAB AND UPADACITINIB EFFICACY, SAFETY PROFILE, AND DURABILITY NORTH CHICAGO, ILL., MAY 5, 2026 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE PRESENTATION OF NEW DATA ACROSS ITS GASTROENTEROLOGY PORTFOLIO AT THE 2026 DIGESTIVE DISEASE WEEK (DDW) ANNUAL MEETING, MAY 2-5 IN CHICAGO.

ABBVIE HIGHLIGHTS NEW LONG-TERM DATA ADVANCING TREATMENT STANDARDS IN INFLAMMATORY BOWEL DISEASES (IBD) AT 2026 DIGESTIVE DISEASE WEEK

MONTREAL, APRIL 30, 2026 (GLOBE NEWSWIRE) -- ABBVIE (NYSE: ABBV), JOINTLY WITH ADMARE BIOINNOVATIONS, TODAY RECOGNIZED RIME THERAPEUTICS AS THE RECIPIENT OF THE ABBVIE BIOTECH INNOVATORS AWARD, A PRIZE DESIGNED TO HELP FOSTER INNOVATION AND SUPPORT GROWTH IN QUEBEC'S LIFE SCIENCES SECTOR.

ABBVIE AND ADMARE BIOINNOVATIONS ANNOUNCE RIME THERAPEUTICS AS ABBVIE BIOTECH INNOVATORS AWARD RECIPIENT IN QUEBEC

THROUGH ITS LOYALTY REWARDS PROGRAM ALL, ALLERGAN AESTHETICS WILL DONATE TO THE SKIN CANCER FOUNDATION $10 FOR EVERY NEW MEMBER WHO JOINS FROM A REFERRAL IN MAY, UP TO $100,000. IRVINE, CALIF.

ALLERGAN AESTHETICS LAUNCHES PHILANTHROPIC EFFORT IN RECOGNITION OF SKIN CANCER AWARENESS MONTH

REPORTS FIRST-QUARTER DILUTED EPS OF $0.39 ON A GAAP BASIS, A DECREASE OF 45.8 PERCENT; ADJUSTED DILUTED EPS OF $2.65, AN INCREASE OF 7.7 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.41 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS FIRST-QUARTER NET REVENUES OF $15.002 BILLION, AN INCREASE OF 12.4 PERCENT ON A REPORTED BASIS OR 10.3 PERCENT ON AN OPERATIONAL BASIS FIRST-QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $7.290 BILLION, AN INCREASE OF 16.4 PERCENT ON A REPORTED BASIS, OR 14.3 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $4.483 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.119 BILLION; GLOBAL HUMIRA NET REVENUES WERE $688 MILLION FIRST-QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.875 BILLION, AN INCREASE OF 26.0 PERCENT ON A REPORTED BASIS, OR 24.3 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $905 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $1.009 BILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $635 MILLION; GLOBAL VYALEV NET REVENUES WERE $201 MILLION FIRST-QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.631 BILLION, A DECREASE OF 0.2 PERCENT ON A REPORTED BASIS, OR 3.0 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VENCLEXTA NET REVENUES WERE $770 MILLION; GLOBAL IMBRUVICA NET REVENUES WERE $556 MILLION; GLOBAL ELAHERE NET REVENUES WERE $198 MILLION FIRST-QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.186 BILLION, AN INCREASE OF 7.6 PERCENT ON A REPORTED BASIS, OR 5.1 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $668 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $232 MILLION RAISES 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $13.96 - $14.16 TO $14.08 - $14.28, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $0.41 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE FIRST QUARTER 2026 NORTH CHICAGO,ILL., APRIL 29, 2026 /PRNEWSWIRE/ -

ABBVIE REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS

SUBMISSION IS SUPPORTED BY DATA FROM THE PHASE 3 UP-AA CLINICAL PROGRAM IN WHICH UPADACITINIB ACHIEVED THE PRIMARY ENDPOINT OF SEVERITY OF ALOPECIA TOOL (SALT) SCORE  20 AT WEEK 24, WITH ADDITIONAL EFFICACY RESULTS OBSERVED AT WEEK 52 1-3 UPADACITINIB IS ALSO THE FIRST JAK INHIBITOR TO MEET THE RANKED SECONDARY ENDPOINT OF COMPLETE SCALP HAIR REGROWTH (SALT = 0) AT WEEK 24 1-3 NORTH CHICAGO, ILL., APRIL 28, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS SUBMITTED AN APPLICATION FOR A NEW INDICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR UPADACITINIB (RINVOQ; 15 MG AND 30 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SEVERE ALOPECIA AREATA (AA), BASED ON RESULTS FROM THE PHASE 3 UP-AA CLINICAL PROGRAM.1-3 "ALOPECIA AREATA IS A CHRONIC IMMUNE-MEDIATED DISEASE IN WHICH THE PHYSICAL AND PSYCHOLOGICAL BURDEN PATIENTS CAN EXPERIENCE GOES FAR BEYOND HAIR LOSS, IMPACTING THEIR DAY-TO-DAY LIVES," SAID KORI WALLACE, M.D.

ABBVIE SUBMITS APPLICATION TO FDA FOR UPADACITINIB (RINVOQ) FOR ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA

BRANFORD, CONN., APRIL 28, 2026 (GLOBE NEWSWIRE) -- EVOLVEIMMUNE THERAPEUTICS, A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY DEVELOPING A NEW CLASS OF MULTI-SPECIFIC T CELL ENGAGERS WITH INTEGRATED CD2 COSTIMULATION, TODAY ANNOUNCED THE NOMINATION OF A DEVELOPMENT CANDIDATE AGAINST A SOLID TUMOR TARGET AS PART OF ITS ONGOING PARTNERSHIP WITH ABBVIE (NYSE:ABBV).

EVOLVEIMMUNE THERAPEUTICS ANNOUNCES ACHIEVEMENT OF PRECLINICAL MILESTONE IN COLLABORATION WITH ABBVIE

SUBMISSION SUPPORTED BY DATA FROM PHASE 3 PIVOTAL AFFIRM STUDY IF APPROVED, ADULT CROHN'S DISEASE PATIENTS WILL HAVE AN ADDITIONAL OPTION FOR INDUCTION OF RISANKIZUMAB-RZAA WHICH IS ALREADY APPROVED FOR INTRAVENOUS (IV) INDUCTION NORTH CHICAGO, ILL., APRIL 27, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT HAS SUBMITTED AN APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SEEKING APPROVAL FOR SKYRIZI (RISANKIZUMAB-RZAA) FOR SUBCUTANEOUS (SC) INDUCTION FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD).

ABBVIE SUBMITS REGULATORY APPLICATION TO FDA FOR SKYRIZI (RISANKIZUMAB-RZAA) SUBCUTANEOUS INDUCTION FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

U.S. FOOD AND DRUG ADMINISTRATION (FDA) ISSUES COMPLETE RESPONSE LETTER (CRL) FOR TRENIBOTULINUMTOXINE (TRENIBOTE) RELATED TO MANUFACTURING PROCESSES; NO ADDITIONAL CLINICAL STUDIES ARE REQUESTED AS THE LEADER IN NEUROTOXIN DEVELOPMENT AND MANUFACTURING, ABBVIE IS WELL POSITIONED TO ADDRESS ALL COMMENTS IN A TIMELY MANNER NORTH CHICAGO, ILL., APRIL 23, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT IT RECEIVED A COMPLETE RESPONSE LETTER (CRL) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGARDING THE BIOLOGICS LICENSE APPLICATION (BLA) FOR TRENIBOTULINUMTOXINE (TRENIBOTE), A FIRST-IN-CLASS BOTULINUM NEUROTOXIN SEROTYPE E WITH A RAPID ONSET OF EFFECT AND SHORT DURATION.

ABBVIE PROVIDES UPDATE ON TRENIBOTULINUMTOXINE (TRENIBOTE) BIOLOGICS LICENSE APPLICATION IN THE U.S.

MARKS ABBVIE'S LARGEST-EVER CAPITAL INVESTMENT IN A SINGLE CAMPUS SINCE ITS INCEPTION INVESTMENT DEMONSTRATES CONTINUED PROGRESS AGAINST ABBVIE'S $100 BILLION COMMITMENT TO U.S. RESEARCH AND DEVELOPMENT (R&D) AND CAPITAL INVESTMENTS, INCLUDING MANUFACTURING, OVER THE NEXT DECADE NEW 185-ACRE CAMPUS WILL CREATE 734 JOBS TO SUPPORT PRODUCTION OF ABBVIE'S IMMUNOLOGY, NEUROSCIENCE AND ONCOLOGY MEDICINES CONSTRUCTION BEGINS IN 2026, WITH COMPLETION EXPECTED BY THE END OF 2028 NORTH CHICAGO, ILL., APRIL 22, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED A $1.4 BILLION INVESTMENT TO BUILD A 185-ACRE PHARMACEUTICAL MANUFACTURING CAMPUS IN DURHAM, NORTH CAROLINA.

ABBVIE SELECTS NORTH CAROLINA FOR NEW $1.4 BILLION MANUFACTURING CAMPUS

TOKYO, JAPAN AND CAMBRIDGE AND LONDON, UK, 20 APRIL 2026  NXERA PHARMA CO., LTD. (NXERA OR THE COMPANY; TSE 4565) ANNOUNCES THAT IT HAS REACHED A THIRD R&D MILESTONE UNDER ITS MULTI-TARGET DISCOVERY COLLABORATION WITH ABBVIE FOCUSED ON NEUROLOGICAL DISEASES, RESULTING IN A PAYMENT OF US$10 MILLION TO NXERA.

NXERA PHARMA TO RECEIVE US$10 MILLION MILESTONE PAYMENT FROM ABBVIE UNDER COLLABORATION TARGETING NEUROLOGICAL DISEASES

THE ENTREPRENEUR AND MOTHER OF FOUR SHARES HER BREAST AUGMENTATION JOURNEY, FROM CONSULTATION TO POST-OP, WITH NATRELLE  BREAST IMPLANTS. AS A CHAMPION OF AUTHENTICITY, LICHY HOPES HER TRANSPARENCY WILL HELP NORMALIZE THE CONVERSATION AROUND BREAST SURGERY.

ERIN LICHY GETS REAL ABOUT HER NATRELLE BREAST AUGMENTATION

BEIJING, APRIL 13, 2026 /PRNEWSWIRE/ --ON APRIL 10, 2026, HAISCO PHARMACEUTICAL GROUP CO., LTD. (TICKER CODE: 002653) ANNOUNCED THAT IT HAS ENTERED INTO AN EXCLUSIVE LICENSING AGREEMENT WITH ABBVIE (NYSE: ABBV), A GLOBAL BIOPHARMACEUTICAL COMPANY.

HAISCO ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH ABBVIE TO DEVELOP NOVEL MEDICINES FOR PAIN

RESULTS FROM THE PHASE 2 IMGN853-0420 TRIAL SHOW AN OBJECTIVE RESPONSE RATE OF 62.7% AND CONSISTENT SAFETY FINDINGS WITH MIRVETUXIMAB SORAVTANSINE-GYNX (ELAHERE  ) PLUS CARBOPLATIN FOLLOWED BY A CONTINUATION OF MIRVETUXIMAB SORAVTANSINE MONOTHERAPY IN PATIENTS WITH 50 % FOLATE RECEPTOR ALPHA (FR)-EXPRESSING, PLATINUM-SENSITIVE OVARIAN CANCER (PSOC). FINDINGS HIGHLIGHT MIRVETUXIMAB SORAVTANSINE'S POTENTIAL ACROSS THE OVARIAN CANCER TREATMENT CONTINUUM.

ABBVIE SHOWCASES LATEBREAKING PHASE 2 DATA FOR MIRVETUXIMAB SORAVTANSINE-GYNX (ELAHERE) IN PLATINUMSENSITIVE OVARIAN CANCER (PSOC) AT SGO 2026

APPLICATIONS ARE OPEN NOW THROUGH APRIL 29 FOR ENTREPRENEURS TO APPLY AND FURTHER UNLOCK THEIR POTENTIAL. SINCE 2023, THE BRAND HAS AWARDED $1.2M TO GRANT WINNERS TO BOOST THEIR BUSINESSES.

BOTOX COSMETIC (ONABOTULINUMTOXINA) EMPOWERS WOMEN ENTREPRENEURS THROUGH "THE CONFIDENCE COLLECTIVE" FOR FOURTH YEAR

THE ALLERGAN MEDICAL INSTITUTE (AMI) AUSTIN LOCATION STRENGTHENS THE NATIONAL TRAINING NETWORK WITH COMPREHENSIVE, HANDS-ON EDUCATION. THE ORANGE COUNTY AND ATLANTA AMI CENTERS CONTINUE DELIVERING BEST-IN-CLASS, EXPERT-LED AESTHETICS TRAINING FOCUSED ON IMPROVING THE TREATMENT EXPERIENCE FOR PATIENTS.

ALLERGAN AESTHETICS THIRD STATE-OF-THE-ART AMI CENTER OPENS IN AUSTIN

FIRST-TIME USERS CAN CLAIM $400 OFF THEIR FIRST BODY CONTOURING TREATMENT. *  IRVINE, CALIF.

ALLERGAN AESTHETICS ANNOUNCES FOURTH ANNUAL, ALL-ACCESS COOLMONTH WITH DEALS ON COOLSCULPTING

NORTH CHICAGO, ILL., MARCH 31, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL ANNOUNCE ITS FIRST-QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, APRIL 29, 2026, BEFORE THE MARKET OPENS.

ABBVIE TO HOST FIRST-QUARTER 2026 EARNINGS CONFERENCE CALL

DATA HIGHLIGHTS EFFICACY AND SAFETY OF RISANKIZUMAB IN PSORIATIC DISEASE, INCLUDING HIGH IMPACT AREAS IN PSORIASIS AND LONG-TERM TREATMENT OF PSORIATIC ARTHRITIS DATA INCLUDES REAL-WORLD EVIDENCE OF MINIMAL DISEASE ACTIVITY AND CLINICAL LONG-TERM SAFETY OUTCOMES OF UPADACITINIB IN ATOPIC DERMATITIS, AS WELL AS INVESTIGATIONAL PHASE 3 DATA FOR VITILIGO AND ALOPECIA AREATA NORTH CHICAGO, ILL., MARCH 27, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED NEW RESEARCH ACROSS ITS DERMATOLOGY PORTFOLIO TO BE PRESENTED AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING, MARCH 2731 IN DENVER, COLORADO.

ABBVIE TO HIGHLIGHT NEW CLINICAL AND REAL-WORLD EVIDENCE ADVANCING STANDARDS OF CARE IN IMMUNE-MEDIATED SKIN DISEASES AT THE 2026 AAD ANNUAL MEETING

PARTNERSHIP EXPANDS "STRIKING OUT CANCER" CAMPAIGN BEGINNING ON OPENING DAY ABBVIE NAMED OFFICIAL PHARMACEUTICAL PARTNER OF MAJOR LEAGUE BASEBALL (MLB), EXPANDING STRIKING OUT CANCER LEAGUE-WIDE STARTING ON OPENING DAY EACH STRIKEOUT WILL TRIGGER A DONATION FROM ABBVIE TO SUPPORT STAND UP TO CANCER INTEGRATED ACROSS EVERY GAME AND KEY MLB EVENTS, STRIKING OUT CANCER TRANSFORMS BASEBALL'S MOST ICONIC MOMENTS INTO SEASON-LONG NATIONAL IMPACT NORTH CHICAGO, ILL., MARCH 24, 2026 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED A MULTI-YEAR PARTNERSHIP WITH MAJOR LEAGUE BASEBALL (MLB), NAMING ABBVIE THE OFFICIAL PHARMACEUTICAL PARTNER OF MLB BEGINNING WITH THE 2026 SEASON.

ABBVIE NAMED OFFICIAL PHARMACEUTICAL PARTNER OF MAJOR LEAGUE BASEBALL

GLOBAL DATA FROM OVER 12,000 CONSUMERS SIGNALS THE FUTURE OF MODERN AESTHETICS WILL BE MULTIMODAL TREATMENT PLANS AND HOLISTIC, NATURAL RESULTS COMPREHENSIVE DATA-BASED EDUCATIONAL SOLUTIONS TO BE PRESENTED AT THE AESTHETIC AND ANTI-AGING MEDICINE WORLD CONGRESS 2026 (AMWC) IN MONACO IRVINE, CALIF., MARCH 19, 2026 /PRNEWSWIRE/ --ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV) AND GLOBAL LEADER IN MEDICAL AESTHETICS, TODAY ANNOUNCED NEW GLOBAL CONSUMER RESEARCH HIGHLIGHTING HOW PATIENT EXPECTATIONS IN MEDICAL AESTHETICS ARE EVOLVING, AND WILL PRESENT THE NEXT EVOLUTION OF ITS AA SIGNATURE FRAMEWORK, TO ADDRESS THIS CHANGING TREATMENT NEED, AT THE AMWC 2026 IN MONACO.

ALLERGAN AESTHETICS REVEALS EVOLUTION IN APPROACH TO MODERN AESTHETIC TREATMENTS WITH COMPREHENSIVE GLOBAL SURVEY AND NEW EDUCATIONAL SOLUTIONS

NEW YORK, NY, MARCH 13, 2026 (GLOBE NEWSWIRE) -- NEW YORK PLASTIC SURGICAL GROUP (NYPS GROUP) AND DEEP BLUE MED SPA (DBMS) ARE PROUD TO ANNOUNCE THAT THEY HAVE ONCE AGAIN BEEN RECOGNIZED BY ALLERGAN AESTHETICS AS THE #1 PROVIDER IN NEW YORK STATE, MARKING THE SECOND CONSECUTIVE YEAR EARNING THIS DISTINCTION. IN ADDITION, THE PRACTICES HAVE BEEN RANKED TOP 50 IN THE NATION FOR 2026, PLACING THEM AMONG AN ELITE GROUP OF AESTHETIC PROVIDERS ACROSS THE UNITED STATES.

AbbVie Inc.

ABBV

Price

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABBV